| Similar Articles |
|---|
 |
The Motley Fool
December 13, 2004
Charly Travers |
PDL Rakes It In A robust revenue stream combined with an exciting drug pipeline is this biotech's recipe for success.   |
The Motley Fool
July 9, 2004
Charly Travers |
Protein Design Labs' Windfall Royalties from Genentech could mean big things for PDL. |
The Motley Fool
August 4, 2004
Charly Travers |
Labs' Report Offers Mixed Results TProtein Design Labs' royalty intake looks great, but its drug development does not. |
The Motley Fool
April 28, 2011
Brian Orelli |
Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable. |
The Motley Fool
March 15, 2005
Charly Travers |
PDL Eyeing Up Profits A timely acquisition is paying off for this drug maker. Investors, take note. |
The Motley Fool
July 14, 2005
Charly Travers |
Dueling Fools: Protein Design Labs Bull Protein Design Labs is a great company for biotech investors. It has a diverse and growing revenue stream, will turn cash-flow positive next year, and has some potential winners in its pipeline to increase the company's value for long-term-minded shareholders. |
The Motley Fool
May 26, 2004
Charly Travers |
Elan and Biogen File for Approval There's a new multiple sclerosis drug on the horizon. |
The Motley Fool
February 18, 2004
Jeff Hwang |
Elan's Early Submission Elan and Biogen Idec will submit a multiple sclerosis treatment ahead of schedule. |
The Motley Fool
May 3, 2005
Charly Travers |
PDL's Well-Stocked Pipeline A broad drug portfolio makes this biotech, Protein Design Labs, a long-term winner. |
The Motley Fool
January 29, 2008
Brian Lawler |
Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected. |
The Motley Fool
August 5, 2005
Charly Travers |
No Surprise Over PDL's Upside Protein Design Labs' overwhelmingly positive earnings release is good news for shareholders. |
The Motley Fool
November 12, 2007
Brian Lawler |
What's New at PDL BioPharma? The past few volatile months are reflected in the third-quarter results from PDL BioPharma. The future, however, may be smoother. Investors, take note. |
The Motley Fool
July 14, 2005
Charly Travers |
Dueling Fools: Protein Design Labs Bull Rebuttal This biotech's tomorrow is coming today. The company is a clear buy at its current market cap near $2 billion. |
The Motley Fool
June 11, 2010
Brian Orelli |
25 to 0! Now That's a Ringing Endorsement Novartis flies through its advisory panel meeting nearly unscathed. |
The Motley Fool
August 29, 2007
Brian Lawler |
PDL Lands in a Hazard The biopharma announces a dramatic shift following the failure of its lead drug. Shares of PDL are down only 19% this morning, presumably because the thought of a leaner and thriftier PDL with its royalty-generating potential is a welcome relief to some investors. |
The Motley Fool
November 29, 2010
Brian Orelli |
There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain. |
The Motley Fool
August 3, 2005
Charly Travers |
Biotech's Big Deal The market is pleased with the partnership between Protein Design Labs and Biogen IDEC. |
The Motley Fool
July 21, 2010
Brian Orelli |
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. |
The Motley Fool
April 14, 2011
Brian Orelli |
Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year. |
The Motley Fool
January 26, 2005
Charly Travers |
Protein Design Muscles Up Biotech company buys itself a bigger future. The company announced that it had acquired privately held ESP Pharma for $300 million cash and $175 million stock. |
The Motley Fool
October 29, 2004
Brian Gorman |
Elan Bides Its Time Is the Irish pharmaceutical stronger from its near-death experience? |
The Motley Fool
June 29, 2004
Charly Travers |
Antegren Gets Priority Review The FDA steps up the drug's time line for approval. |
The Motley Fool
March 3, 2011
Brian Orelli |
3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year. |
The Motley Fool
August 29, 2006
Brian Lawler |
More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note. |
The Motley Fool
March 8, 2005
Charly Travers |
After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market. |
The Motley Fool
February 10, 2010
Brian Orelli |
Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause. |
The Motley Fool
November 21, 2007
Brian Lawler |
Elan and Biogen Denied Elan's multiple sclerosis treatment is denied a label expansion in Europe. Investors, take note. |
The Motley Fool
December 16, 2011
Brian Orelli |
Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value. |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
The Motley Fool
February 27, 2007
Brian Lawler |
PDL Keeps Us Waiting PDL BioPharma announces its year-end financial results. Investors, take note. |
The Motley Fool
October 5, 2006
Brian Lawler |
Elan Extends Tysabri's Reach The MS-fighting drug gains approval in Canada. Next month, when Biogen and Elan report third-quarter results, investors will get a preliminary indication of how these sales of Tysabri are ramping up. |
The Motley Fool
January 31, 2007
Brian Lawler |
FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer. |
The Motley Fool
April 14, 2008
Brian Lawler |
Not a Bad Quarter for Genentech Two of its top drugs see speedy growth, but investors don't seem ecstatic about Genentech's first-quarter financial results. |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
The Motley Fool
November 24, 2004
Charly Travers |
A Blockbuster Drug Gains Approval Biogen IDEC and Elan announced that Tysabri had been approved by the FDA for the treatment of muliple sclerosis (MS). Tysabri has long been regarded as a drug that will generate a whopping level of sales. |
The Motley Fool
February 6, 2008
Brian Lawler |
PDL BioPharma Regroups, Piece by Piece The company still brings in plenty of money, despite selling off assets. Investors, take note. |
The Motley Fool
June 8, 2010
Brian Orelli |
Injecting Uncertainty Into the Multiple Sclerosis Market Novartis' oral MS drug could be a blockbuster -- if it can get past the FDA. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
February 8, 2005
Charly Travers |
Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance. |
The Motley Fool
May 5, 2006
Stephen D. Simpson |
Biogen Idec Needs a Booster Tysabri had better come back strong, or growth could come up short for this biotech. Investors, take note. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
April 12, 2011
Brian Orelli |
How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands. |
The Motley Fool
July 8, 2004
Charly Travers |
Genentech's Next Billion-Dollar Drug The cancer drug Avastin looks like a big winner. The market had exceptionally high expectations for this product, and it certainly seems well on its way to becoming a blockbuster drug. |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
The Motley Fool
May 26, 2010
Brian Orelli |
Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming. |
The Motley Fool
August 19, 2010
Brian Orelli |
High Risk, High Reward. At Least It Was Cheap! Biogen licenses a drug to treat ALS. |
The Motley Fool
August 10, 2010
Brian Orelli |
Elan's Alternative to Strategic Alternatives Sometimes doing nothing is the best option. |
The Motley Fool
April 14, 2008
Brian Lawler |
PDL BioPharma's Split Decision PDL BioPharma is finally taking further steps to try to realize better value for the different parts of its business. |
Chemistry World
February 27, 2013
Andrew Turley |
Talk of a $6.6bn deal for Elan Irish drug maker Elan has been surprised by a potential $6.6 billion offer being mooted by investment firm Royalty Pharma. |
The Motley Fool
April 6, 2011
Brian Orelli |
Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire. |
